Innovimmune Biotherapeutics, Inc.

5 articles about Innovimmune Biotherapeutics, Inc.

• APEIRON EXPANDS EXECUTIVE BOARD AND APPOINTS DR. ANDERSON GAWECO AS CHIEF MEDICAL AND SCIENTIFIC OFFICER (CMSO)

  8/28/2018

  APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).

• Innovimmune Biotherapeutics, Inc. To Present Superior Preclinical Therapeutic Efficacy Results In Rheumatoid Arthritis Of Its INV-17 ROR Gamma T Inhibitor Program At The 2014 American College of Rheumatology Annual Meeting

  11/5/2014

• Innovimmune Biotherapeutics, Inc.'s Preclinical Data On Highly Selective ROR Gamma Inhibitor Prevents Multiple Sclerosis In Mice

  1/15/2014

• Start-up Innovimmune Biotherapeutics, Inc. Pursues Pharma Partners, Shuns VCs

  8/7/2012

• Innovimmune Biotherapeutics, Inc. Receives National Institutes of Health (NIH) Grant for Development of Novel Automimmune Compounds

  6/13/2012